YF-VAX 1 dose vials
Ended Awarded Last action
- Contract number
- SPE2DR26FJNV5
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $2,227
Award facts
- Contract value 100% obligated
- $2,227.04 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $2,227.04 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for YF-VAX (yellow fever vaccine) in single-dose vials. This firm fixed-price delivery order, issued on November 25, 2025, with an ultimate completion date of December 17, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award was executed under DMS Pharmaceutical Group's broader Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499.9 billion vehicle established to supply pharmaceutical products and medical consumables to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has emerged as a critical supplier within the federal pharmaceutical supply chain, holding a single-award IDC under the PPV-G GEN V program with a ceiling value of $499,999,999 and a completion date of December 31, 2036. The contract encompasses a 30-month base period with three 30-month option periods and authorizes DLA to issue delivery orders for branded and generic prescription medications, over-the-counter drugs, biologics, vaccines, and medical consumables. The company's extensive product portfolio and demonstrated performance across multiple recent delivery orders position it as a key regional prime vendor contractor within the broader $30.3 billion PPV-G GEN V acquisition strategy designed to support recurring medical supply needs of the Department of Defense globally.
Quick answers
Who was awarded contract SPE2DR26FJNV5?
SPE2DR26FJNV5 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 25, 2025.
How much is contract SPE2DR26FJNV5 worth?
The government has obligated $2,227 on SPE2DR26FJNV5.
Is contract SPE2DR26FJNV5 an order under another contract?
Yes. SPE2DR26FJNV5 is a delivery order under SPE2DR25D9226, an indefinite delivery contract.
Was contract SPE2DR26FJNV5 competed?
The extent of competition for SPE2DR26FJNV5 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award